

2018 Shenzhen Pingshan International Biopharmaceutical Industry Innovation & Development Summit



Oxford 21 September 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today that CEO Professor Nick La Thangue presented to the Shenzhen Pingshan International Biopharmaceutical Summit on “Development Status and Trends in Global Cancer Medicine”, run by the Shenzhen Pingshan Economic and Technology Promotion Bureau, China/The People’s Government of Pingshan District Shenzhen Municipality.

The meeting focused on innovation and development in The Shenzhen Pingshan region and potential for the biopharmaceutical sector to bring economic growth in the region.

Professor La Thangue said “*I am very pleased to have had the opportunity to present at this important meeting and to discuss the novel research and the exciting clinical plans which could lead to significant benefit for cancer patients. The Shenzhen Pingshan Economic and Technology Bureau offers exciting opportunities for corporate growth*”.

The “2018 Shenzhen International Biological and Life Health Industry Exhibition and BT Leaders Summit is an important meeting of more than 100 academicians, venture capital institutions and well-known corporate leaders, experts and scholars from universities and colleges at home and abroad”. **Shenzhen Pingshan Economic Technology Promotion Bureau.**





About Celleron Therapeutics Limited

Celleron Therapeutics is advancing a clinical pipeline of precision therapies for different cancer indications. The company has built a proprietary platform around epigenetic control and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron's approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy. The company is a spin-out from Oxford University and located on the Oxford Science Park. Celleron has a global license partnership with Astra Zeneca and is initiating new trials in China through its Chinese partner Nuance. The company secured investment in 2016 from a consortium of South Korean investors. For more information see www.cellerontherapeutics.com

Celleron Therapeutics Ltd,
Magdalen Centre, Oxford Science Park,
Robert Robinson Avenue,
Oxford OX4 4GA, UK

Email: enquiries@cellerontherapeutics.com
www.cellerontherapeutics.com

Registered in England Reg. No. 5162047
VAT Reg No 934078417
Trademark Registered in UK